Advisory Issued on Erythropoietin and CKD Patients
In response to a study published in the New England Journal of Medicine (2006;355: 2085-2098) and covered extensively in the lay media, the FDA has issued a public health advisory on the use of erythropoiesis-stimulating agents (ESAs), also known as recombinant human erythropoietin, for treating patients with CKD anemia.
The e-mail address(es) that you supply to use this service will only be used to send the requested article.